Castle Biosciences (CSTL) Equity Income (2024 - 2026)

Castle Biosciences has disclosed Equity Income across 3 years of filings, most recently posting $2.0 million for Q1 2026.

• Equity Income for Q1 2026 came in at $2.0 million, up 241.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (up 669.2% YoY), and the FY2025 annual result was $1.5 million, up 164.14% from the prior year.
• Equity Income came in at $2.0 million for Q1 2026 at Castle Biosciences, up from -$1.9 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $3.6 million in Q3 2025 to a low of -$1.9 million in Q4 2025.
• The 3-year median for Equity Income is $870000.0 (2024), against an average of $680333.3.
• Across the five-year window, Equity Income slumped 434.23% in 2025 and jumped 241.89% in 2026, its largest moves.
• Castle Biosciences' Equity Income stood at $555000.0 in 2024, then plunged by 434.23% to -$1.9 million in 2025, then surged by 209.0% to $2.0 million in 2026.
• The last three Equity Income figures came in at $2.0 million (Q1 2026), -$1.9 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.